Qiagen (NYSE:QGEN) has put AI at the center of its story this month by launching the QIA Agent digital assistant for lab workflows and expanding its AI collaboration with NVIDIA in bioinformatics and drug discovery.

Despite the AI announcements and a higher proposed dividend, Qiagen’s short term momentum is mixed, with the share price up over the past week but down about 26% year to date, and longer term total shareholder returns also negative.

If Qiagen’s push into AI tools has caught your attention, it can be useful to compare it with other specialists using artificial intelligence in healthcare. You can start with 34 healthcare AI stocks

With Qiagen’s share price down over the past year despite AI launches and a higher proposed dividend, the key question is whether the current valuation still reflects too much caution or if the market is already pricing in future growth.

Most Popular Narrative: 34.3% Undervalued

Qiagen’s most followed narrative pegs fair value at $53.53 versus a last close of $35.17, framing a wide gap that hinges on execution in diagnostics and automation.

The accelerated adoption of automation and digital workflows in both clinical and research settings, as seen with the development and imminent launch of three new high-throughput, digitally-connected automated sample prep systems, positions Qiagen to address increasing throughput and efficiency needs, supporting both top-line growth and operating margin improvement in coming years.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that confidence in higher margins and recurring revenue, and how those expectations feed into the discount rate and earnings path? The full narrative lays out a specific revenue ramp, profitability lift, and valuation multiple that underpin the $53.53 figure.

Result: Fair Value of $53.53 (UNDERVALUED)

However, that upside narrative can be challenged if life sciences funding stays weak or if competition in digital PCR and syndromic testing tightens more than expected.

Next Steps

With optimism about AI and concern about funding and competition both in play, this is the moment to look at the facts yourself and decide where you stand, then weigh up the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop here, you might miss stocks that better match your goals, so use the screener to quickly surface ideas that fit your style.

• Target steady income by zeroing in on companies that appear to offer stronger payouts than average through the 10 dividend fortresses.
• Hunt for potential upside by focusing on companies that combine quality with attractive prices using the 49 high quality undervalued stocks.
• Prioritize resilience by filtering for companies with strong financial footing and sensible debt levels via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.